CRIS Current Research Information System

FOLLO, MATILDE YUNG
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.555
AS - Asia 7.378
EU - Europa 6.299
AF - Africa 681
SA - Sud America 403
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 17
Totale 23.352
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.420
SG - Singapore 2.235
CN - Cina 1.805
VN - Vietnam 1.646
IT - Italia 1.640
GB - Regno Unito 1.196
DE - Germania 853
SE - Svezia 767
HK - Hong Kong 487
FR - Francia 341
IN - India 326
RU - Federazione Russa 266
BR - Brasile 264
IE - Irlanda 192
NL - Olanda 178
FI - Finlandia 172
BD - Bangladesh 171
JP - Giappone 169
TG - Togo 164
KR - Corea 140
UA - Ucraina 136
SC - Seychelles 133
ZA - Sudafrica 130
CI - Costa d'Avorio 107
NG - Nigeria 99
EE - Estonia 88
HR - Croazia 85
CA - Canada 79
BG - Bulgaria 65
AR - Argentina 63
CH - Svizzera 63
AT - Austria 56
PK - Pakistan 56
ID - Indonesia 48
BE - Belgio 47
JO - Giordania 44
PH - Filippine 43
TH - Thailandia 34
PL - Polonia 32
MX - Messico 31
TR - Turchia 30
ES - Italia 25
TW - Taiwan 23
GR - Grecia 20
PT - Portogallo 19
EC - Ecuador 17
CO - Colombia 16
IQ - Iraq 16
RO - Romania 16
EU - Europa 15
UZ - Uzbekistan 15
AU - Australia 14
IR - Iran 14
VE - Venezuela 13
IL - Israele 12
PY - Paraguay 12
SA - Arabia Saudita 11
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
MY - Malesia 9
LB - Libano 8
NP - Nepal 7
CL - Cile 6
DZ - Algeria 6
JM - Giamaica 6
KE - Kenya 5
PE - Perù 5
TN - Tunisia 5
UY - Uruguay 5
AZ - Azerbaigian 4
ET - Etiopia 4
GT - Guatemala 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CY - Cipro 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BZ - Belize 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GE - Georgia 2
HU - Ungheria 2
MK - Macedonia 2
NO - Norvegia 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 23.327
Salva come PNG Salva come JPEG
Città #
Singapore 1.569
Southend 1.038
Ashburn 926
Fairfield 741
Chandler 657
Bologna 566
Santa Clara 472
Hong Kong 463
San Jose 446
Houston 429
Ann Arbor 353
Woodbridge 336
Wilmington 318
Ho Chi Minh City 313
Seattle 298
Hefei 277
Hanoi 273
Cambridge 256
Princeton 247
Beijing 239
Boardman 207
Dublin 193
Lomé 164
Dong Ket 149
Dallas 142
Helsinki 131
Lauterbourg 121
New York 118
Milan 115
Tokyo 115
Frankfurt am Main 109
Padova 109
Nanjing 108
Seoul 108
Abidjan 107
Westminster 106
Abeokuta 96
Los Angeles 92
Council Bluffs 86
Berlin 75
Buffalo 75
Sofia 65
Jacksonville 61
Shenyang 60
Jinan 58
Munich 55
Saint Petersburg 54
Redondo Beach 53
Rome 51
Turin 50
Changsha 48
Da Nang 48
Redwood City 48
Florence 47
San Diego 47
Bern 46
Medford 45
Brussels 44
Guangzhou 44
Amman 42
Haiphong 41
Vienna 41
Bremen 37
Nanchang 34
Redmond 34
Hebei 33
Shanghai 33
São Paulo 31
Johannesburg 30
Des Moines 29
Toronto 28
Chicago 27
Tianjin 27
Jakarta 26
Amsterdam 24
Bengaluru 24
Hangzhou 24
Orem 24
San Francisco 24
London 23
Nuremberg 23
Warsaw 23
Dearborn 22
Lappeenranta 22
Udine 22
Zhengzhou 22
Phoenix 21
Rawalpindi 21
Atlanta 20
Jiaxing 19
Montreal 19
Parma 19
Turku 19
Brooklyn 18
Falkenstein 18
Falls Church 18
Chennai 17
Hải Dương 17
Norwalk 17
Yubileyny 17
Totale 14.697
Salva come PNG Salva come JPEG
Nome #
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 308
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 291
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 282
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 263
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 254
Inositide-Dependent Nuclear Signalling in Health and Disease 251
Cancer therapy and treatments during COVID-19 era 243
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 233
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 231
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 228
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 228
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 227
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 227
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 225
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 225
Perinatal Stem Cell Spheroids: Insights into Immunomodulation for Type 1 Diabetes Therapy 224
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 219
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 217
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 215
Nuclear inositide signaling and cell cycle 213
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 213
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 210
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 210
Specific presence of PKC isoforms in low and fast proliferation Moris hepatoma cells 209
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 208
Effect of PKC inhibition on low and fast proliferating Morris rat hepatoma cell line progression 207
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders 207
Nuclear Inositide Signaling via Phospholipase C 206
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 204
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 203
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 202
Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression 202
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 202
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 201
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 198
Revisiting nuclear phospholipase C signalling in MDS 195
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 193
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 188
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 188
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 187
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 187
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study 186
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 186
Inositide signaling in the nucleus: From physiology to pathology. 185
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 184
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 184
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 184
Advances in MDS/AML and inositide signalling 183
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 183
Physiology and pathology of nuclear phospholipase C beta1 182
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy 178
Nuclear phospholipase C beta1 and cellular differentiation. 175
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 175
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 175
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 174
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 174
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies 173
Protein kinase C involvement in cell cycle modulation 171
Nuclear inositol lipid metabolism: more than just second messenger generation? 171
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 170
Nuclear Phosphoinositides as Key Determinants of Nuclear Functions 169
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 168
Nuclear Nox4-Derived Reactive Oxygen Species in Myelodysplastic Syndromes 165
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 164
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 163
PLC and PI3K/Akt/mTOR signalling in disease and cancer 162
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 162
Phosphoinositide 3 Kinase signaling in human stem cells from reprogramming to differentiation: A tale in cytoplasmic and nuclear compartments 162
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 161
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 160
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 158
PKR Activity Is Required for Acute Leukemic Cell Maintenance and Growth: A Role for PKR-Mediated Phosphatase Activity to Regulate GSK-3 Phosphorylation. 158
Unravelling Heterogeneity of Amplified Human Amniotic Fluid Stem Cells Sub-Populations 158
Modulation of nuclear PI-PLCbeta1 during cell differentiation 156
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 156
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 154
The physiology and pathology of inositide signaling in the nucleus 153
Nuclear inositide signaling in myelodysplastic syndromes. 151
Nuclear PI-PLCβ1: An appraisal on targets and pathology 151
Molecular Mechanisms Underlying Psychological Stress and Cancer 151
Recent advances in MDS mutation landscape: Splicing and signalling 150
Nuclear PI-PLCbeta1-Lamin B1 complex signalling during cell cycle progression in human erytholeukemia cells 149
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 149
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 149
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 148
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53 147
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 145
null 144
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression 143
PI-PLCβ1 gene copy number alterations in breast cancer 143
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 141
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 140
Nuclear Phospholipids and Signaling: An Update of the Story 140
PKC inhibitors induced apoptosis in Morris hepatoma 139
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 139
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 139
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. 137
Molecular taxonomy of myelodysplastic syndromes and its clinical implications 136
Totale 18.656
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.723
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021563 0 0 0 0 0 0 0 0 0 0 0 563
2021/20222.543 261 37 167 203 226 130 79 147 91 353 418 431
2022/20233.006 282 389 163 401 275 245 162 197 463 61 201 167
2023/20241.097 68 165 98 88 135 164 36 47 68 102 55 71
2024/20253.333 142 429 300 191 608 165 306 123 72 181 149 667
2025/20268.005 625 803 727 510 974 518 921 250 1.417 546 374 340
Totale 23.946